MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

Discover tips for managing swelling, redness, and pain at subcutaneous immunoglobulin (SCIg) infusion sites for primary ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...

Reducing pembrolizumab infusions from 30 minutes to 10 minutes could be a safe alternative for patients and open hundreds of ...

Merck has talked up the value of its subcutaneous version of Keytruda, arguing that the investigational therapy will increase access to treatment by untethering patients from infusion centers. Roche ...

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and ...

MAHWAH, N.J., November 17, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on innovative and ...

Rystiggo is administered weekly, 3ml to 6ml over 15 to 30 minutes for six weeks.

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...